预期2017年ICPT会有机会，主要是看好NASH。这种股票不宜重仓，但可以地量或量能初启时介入，暴量是撤离。
目前是我四个生药持仓股末位（依次是REGN,CELG,INCY,ICPT).
WENXUECITY.COM does not represent or guarantee the truthfulness, accuracy, or reliability of any of communications posted by other users.
Copyright ©1998-2024 wenxuecity.com All rights reserved. Privacy Statement & Terms of Use & User Privacy Protection Policy
